RxDoctor Payments Data

Blake Stone

Family · Fredericksburg, VANPI 1447956305

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 62 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$454
  • Mylan Specialty L.p.$289
  • Viatris Specialty LLC$194
  • GSK$48
  • Eagle Pharmaceuticals, Inc.$21
  • Inspire Medical Systems, Inc.$17

What the payments were for

  • Food & beverage$95693%
  • Education$687%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,024 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$42,630
Medicare patients
238
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$132,591
Breztri AerosphereBudesonide/Glycopyr/Formoterol129$99,240
Pirfenidone13$56,128
Spiriva RespimatTiotropium Bromide56$39,972
Breo ElliptaFluticasone/Vilanterol45$27,234
Stiolto RespimatTiotropium Br/Olodaterol Hcl50$25,033
Arnuity ElliptaFluticasone Furoate61$14,655
Advair HfaFluticasone Propion/Salmeterol28$13,214
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,039
Albuterol Sulfate HfaAlbuterol Sulfate356$9,027
SymbicortBudesonide/Formoterol Fumarate23$8,266
Ipratropium Bromide96$4,853
Roflumilast63$4,561
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,345
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$48$183,518278 claims
AstraZenecaBreztri Aerosphere, Symbicort$454$107,506152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →